|
内容記述 |
Excessive wound contraction can lead to hypertrophic scarring, resulting in significant disadvantages in terms of appearance and functioning. Decorin (DCN) has shown therapeutic effects on excessive skin contraction in vitro; however, in vivo effects have not been observed. We synthesized and purified recombinant human DCN, added it to a dermal substitute, and applied it to full-thickness skin defects in mice to analyze its effect on skin contracture. Digital photographs of the open wound area in each group were captured, and the wounds were excised on days 4, 8, and 13. Hematoxylin and eosin and immunohistochemical staining (DCN, αSMA and Gr-1) were performed with all sections. Furthermore, the length of wound contraction and re-epithelialization and the density of αSMA expression were determined. Gr-1-positive cells were counted. The wound area was wider in the DCN group on days 4 and 8 but was comparable on day 13. With DCN, the length of wound contraction was shorter, and the density of αSMA expression was lower. This result indicated that the duration of wound closure was comparable; however, the DCN group showed lower wound contraction than the control group. For DCN, the length of re-epithelialization on day 8 was shorter; however, it was longer on day 13. This result indicates that re-epidermalization in the DCN group was delayed in the middle of the process but eventually accelerated, and epidermalization was more advanced than in the control group. The number of neutrophils (Gr-1+) was lower on all observation days. In the future, the decorin administration to the dermal substitute or decorin-added dermal substitute can be a treatment strategy for the prevention of excessive wound contraction caused by hypertrophic scarring. |
48(1)43-53.pdf (13.7 MB)
